Literature DB >> 31678251

Unique Impacts of Methionine Oxidation, Tryptophan Oxidation, and Asparagine Deamidation on Antibody Stability and Aggregation.

Magfur E Alam1, Thomas R Slaney2, Lina Wu3, Tapan K Das2, Sambit Kar2, Gregory V Barnett2, Anthony Leone2, Peter M Tessier4.   

Abstract

Monoclonal antibodies are attractive therapeutic agents because of their impressive biological activities and favorable biophysical properties. Nevertheless, antibodies are susceptible to various types of chemical modifications, and the impact of such modifications on antibody physical stability and aggregation remains understudied. Here, we report a systematic analysis of the impact of methionine oxidation, tryptophan oxidation, and asparagine deamidation on antibody conformational and colloidal stability, hydrophobicity, solubility, and aggregation. Interestingly, we find little correlation between the impact of these chemical modifications on antibody conformational stability and aggregation. Methionine oxidation leads to significant reductions in antibody conformational stability while having little impact on antibody aggregation except at extreme conditions (low pH and elevated temperature). Conversely, tryptophan oxidation and asparagine deamidation have little impact on antibody conformational stability while promoting aggregation at a wide range of solution conditions, and the aggregation mechanisms appear linked to unique types of reducible and nonreducible covalent crosslinks and, in some cases, to increased levels of attractive colloidal interactions. These findings highlight that even related types of chemical modifications can lead to dissimilar antibody aggregation mechanisms, and evaluating these findings for additional antibodies will be important for improving the systematic generation of antibodies with high chemical and physical stability.
Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  developability; formulation; mAb; protein aggregation; solubility

Year:  2019        PMID: 31678251     DOI: 10.1016/j.xphs.2019.10.051

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

Review 1.  Recombinant antibodies aggregation and overcoming strategies in CHO cells.

Authors:  Tingting Xu; Jihong Zhang; Tianyun Wang; Xiaoyin Wang
Journal:  Appl Microbiol Biotechnol       Date:  2022-05-24       Impact factor: 4.813

2.  Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries.

Authors:  Andre Azevedo Reis Teixeira; Michael Frank Erasmus; Sara D'Angelo; Leslie Naranjo; Fortunato Ferrara; Camila Leal-Lopes; Oliver Durrant; Cecile Galmiche; Aleardo Morelli; Anthony Scott-Tucker; Andrew Raymon Morton Bradbury
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

3.  Aggregation Time Machine: A Platform for the Prediction and Optimization of Long-Term Antibody Stability Using Short-Term Kinetic Analysis.

Authors:  Marko Bunc; San Hadži; Christian Graf; Matjaž Bončina; Jurij Lah
Journal:  J Med Chem       Date:  2022-01-28       Impact factor: 7.446

4.  Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB11, as Lucentis® (Ranibizumab) Biosimilar.

Authors:  Eunji Kim; Jihyeon Han; Yunjung Chae; Hyerim Park; Saerom Kim; Seokkyun Kim; Jungmin Lee; Beom Chan Kim
Journal:  Ophthalmol Ther       Date:  2022-01-27

Review 5.  In silico prediction of post-translational modifications in therapeutic antibodies.

Authors:  Shabdita Vatsa
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

Review 6.  Photo-Oxidation of Therapeutic Protein Formulations: From Radical Formation to Analytical Techniques.

Authors:  Elena Hipper; Michaela Blech; Dariush Hinderberger; Patrick Garidel; Wolfgang Kaiser
Journal:  Pharmaceutics       Date:  2021-12-28       Impact factor: 6.321

Review 7.  Protein aggregation and immunogenicity of biotherapeutics.

Authors:  Ngoc B Pham; Wilson S Meng
Journal:  Int J Pharm       Date:  2020-06-09       Impact factor: 5.875

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.